Compare LYTS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | CSTL |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.9M | 806.3M |
| IPO Year | 1994 | 2019 |
| Metric | LYTS | CSTL |
|---|---|---|
| Price | $23.95 | $24.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $27.50 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 390.6K | 257.3K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $573,377,000.00 | $344,229,000.00 |
| Revenue This Year | $16.20 | $2.42 |
| Revenue Next Year | $27.71 | $12.69 |
| P/E Ratio | $56.05 | ★ N/A |
| Revenue Growth | ★ 22.09 | 3.66 |
| 52 Week Low | $15.31 | $14.59 |
| 52 Week High | $24.75 | $44.28 |
| Indicator | LYTS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 48.26 |
| Support Level | $21.76 | $21.77 |
| Resistance Level | $23.99 | $26.20 |
| Average True Range (ATR) | 0.87 | 0.96 |
| MACD | 0.44 | 0.19 |
| Stochastic Oscillator | 88.45 | 63.98 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.